Table 1.
Baseline characteristics of prospective clinical cohort
| Demographics | Value |
|---|---|
| Number of participants | 49 |
| Age (years) | 67 ± 9 |
| Male/Female | 32/17 |
| Caucasian (%) | 94 |
| COPD-related variable | |
| LAMA use (n,%) | 45 (91.8%) |
| Inhaled corticosteroid use (n,%) | 43 (87.5%) |
| LABA use (n,%) | 40 (81.6%) |
| Current smoker (%) | 57.1 |
| Smoking history (pack-years) | 50 (39,63) |
| Radiographic emphysema (%) | 90.6 |
| Home O2 (%) | 38.3 |
| FEV1 (L) | 1.1 ± 0.47 |
| FEV1 (%Predicted) | 41 ± 18 |
| Self-reported AECOPD in last 1-year | 2 (0,4) |
| Self-reported Admission for AECOPD in last 1-year | 0 (0,1) |
LAMA long-acting muscarinic antagonist, FEV1 forced expiratory volume in 1-s, AECOPD acute exacerbation of chronic obstructive pulmonary disease